NCT05203458View on ClinicalTrials.gov

Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients

CompletedOBSERVATIONAL

Enrollment

3,136

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

July 5, 2023

Study Completion Date

July 5, 2023

Conditions

Breast Cancer, HER2

Trial Locations (7)

Unknown

Research Site, Shanghai

Research Site, Guangzhou

Research Site, Jinan

Research Site, Shenyang

Research Site, Wuhan

Research Site, Xi'an

Research Site, Zhengzhou

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY